CA2742968A1 - Bibliotheques combinatoires d'anticorps et leurs utilisations - Google Patents
Bibliotheques combinatoires d'anticorps et leurs utilisations Download PDFInfo
- Publication number
- CA2742968A1 CA2742968A1 CA2742968A CA2742968A CA2742968A1 CA 2742968 A1 CA2742968 A1 CA 2742968A1 CA 2742968 A CA2742968 A CA 2742968A CA 2742968 A CA2742968 A CA 2742968A CA 2742968 A1 CA2742968 A1 CA 2742968A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- library
- chain
- germline
- combinatorial antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Structural Engineering (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
Abstract
L'invention porte sur des procédés permettant lélaboration d'une bibliothèque combinatoire d'anticorps à partir de segments de lignée germinale humaine. L'invention porte également sur des bibliothèques de molécules d'acide nucléique élaborées à partir de segments de lignée germinale codant pour des chaînes VL, sur des bibliothèques de molécules d'acide nucléique codant pour des chaînes VH, et sur les bibliothèques d'anticorps ainsi obtenues. Les bibliothèques sont élaborées sous forme de bibliothèques adressables. L'invention porte sur des procédés de criblage de bibliothèques d'anticorps contre un antigène protéique cible et sur les anticorps identifiés ou sélectionnés.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19876408P | 2008-11-07 | 2008-11-07 | |
US61/198,764 | 2008-11-07 | ||
US21120409P | 2009-03-25 | 2009-03-25 | |
US61/211,204 | 2009-03-25 | ||
PCT/US2009/063299 WO2010054007A1 (fr) | 2008-11-07 | 2009-11-04 | Bibliothèques combinatoires d'anticorps et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2742968A1 true CA2742968A1 (fr) | 2010-05-14 |
CA2742968C CA2742968C (fr) | 2020-06-09 |
Family
ID=41508157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2742969A Abandoned CA2742969A1 (fr) | 2008-11-07 | 2009-11-04 | Anticorps anti-dll4 et utilisations associees |
CA2742968A Expired - Fee Related CA2742968C (fr) | 2008-11-07 | 2009-11-04 | Bibliotheques combinatoires d'anticorps et leurs utilisations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2742969A Abandoned CA2742969A1 (fr) | 2008-11-07 | 2009-11-04 | Anticorps anti-dll4 et utilisations associees |
Country Status (7)
Country | Link |
---|---|
US (4) | US9221902B2 (fr) |
EP (2) | EP2356146A1 (fr) |
JP (4) | JP2012508017A (fr) |
AU (4) | AU2009313560B2 (fr) |
CA (2) | CA2742969A1 (fr) |
DK (1) | DK2356270T3 (fr) |
WO (2) | WO2010054010A1 (fr) |
Families Citing this family (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
WO2008042236A2 (fr) | 2006-09-29 | 2008-04-10 | Oncomed Pharmaceuticals, Inc. | Compositions et procédés permettant de diagnostiquer et de traiter le cancer |
CA2687141C (fr) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions et procedes pour produire des proteines de fusion bioactives |
US8524233B2 (en) | 2008-03-14 | 2013-09-03 | Biocon Limited & Centro de Immunologia Molecular | Monoclonal antibody and a method thereof |
DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
WO2010108153A2 (fr) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Immunoglobulines porteuses et utilisations de celles-ci |
WO2010121370A1 (fr) * | 2009-04-20 | 2010-10-28 | University Health Network | Signature de l'expression d'un gène de pronostic pour un carcinome squameux du poumon |
DK2435568T3 (da) | 2009-05-29 | 2014-09-08 | Morphosys Ag | Samling af syntetiske antistoffer til behandling af sygdom |
TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
EP2493497A4 (fr) * | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | Inhibition de notch pour le traitement et la prévention de l'obésité et du syndrome métabolique |
US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
WO2015200538A1 (fr) * | 2014-06-24 | 2015-12-30 | Procept Biorobotics Corporation | Échantillonnage de tissus et procédés et appareil pour le traitement du cancer |
US10016620B2 (en) | 2010-02-04 | 2018-07-10 | Procept Biorobotics Incorporation | Tissue sampling and cancer treatment apparatus |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
HUE026229T2 (en) | 2010-02-08 | 2016-06-28 | Regeneron Pharma | Common light chain mouse |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
DK3336225T3 (da) * | 2010-07-16 | 2020-03-30 | Adimab Llc | Antistofbiblioteker |
KR20130048242A (ko) * | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
EP2725034B1 (fr) | 2010-09-22 | 2019-04-03 | Amgen Inc. | Immunoglobulines porteuses sans spécificité pour les tissus humains et leurs utilisations |
SG10201509257VA (en) | 2010-11-19 | 2015-12-30 | Morphosys Ag | A collection and methods for its use |
ES2861595T3 (es) * | 2011-04-28 | 2021-10-06 | Univ Leland Stanford Junior | Identificación de polinucleótidos asociados a una muestra |
WO2012149536A1 (fr) * | 2011-04-28 | 2012-11-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Anticorps de neutralisation contre virus nipah et hendra |
MX347691B (es) | 2011-05-04 | 2017-05-09 | Omeros Corp | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. |
AR086924A1 (es) * | 2011-06-15 | 2014-01-29 | Hoffmann La Roche | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion |
EP2739740B1 (fr) | 2011-08-05 | 2019-10-02 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne légère universelle humanisée |
JP6244301B2 (ja) * | 2011-08-18 | 2017-12-06 | アフィニティ バイオサイエンス ピーティーワイ リミテッド | 可溶性ポリペプチド |
EP3485903B1 (fr) | 2011-09-23 | 2022-11-16 | Mereo BioPharma 5, Inc. | Agents de liaison à vegf/dll4 et leurs utilisations |
AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
CN104053671A (zh) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | 治疗癌症的抗体和方法 |
EP3663314A1 (fr) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Anticorps humanisés avec cdr3s ultralong |
JP6684490B2 (ja) | 2012-01-09 | 2020-04-22 | ザ・スクリップス・リサーチ・インスティテュート | 超長相補性決定領域及びその使用 |
SI2809681T1 (sl) * | 2012-01-31 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | Protitelesa anti-asic1 in njihova uporaba |
WO2013131074A1 (fr) * | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Procédés et réactifs pour évaluer une maladie auto-immune et déterminer un répertoire d'anticorps |
CN104379602B (zh) | 2012-03-08 | 2017-05-03 | 哈洛齐梅公司 | 具有条件活性的抗表皮生长因子受体抗体及其使用方法 |
US10519245B2 (en) | 2012-06-21 | 2019-12-31 | Sorrento Therapeutics Inc. | Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer |
KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
WO2014052713A2 (fr) | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Protéines de liaison à her2 et vegf-a à stabilité améliorée |
US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
JP6371294B2 (ja) * | 2012-10-31 | 2018-08-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Dll4アンタゴニストによる処置の方法およびモニタリング |
AU2013341349A1 (en) * | 2012-11-06 | 2015-05-21 | Medimmune Limited | Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules |
US10407503B2 (en) * | 2012-11-30 | 2019-09-10 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-Met |
JP6306605B2 (ja) | 2012-12-05 | 2018-04-04 | ノバルティス アーゲー | Epoを標的とする抗体のための組成物および方法 |
AU2014210475B2 (en) * | 2013-01-24 | 2017-03-02 | Abtlas Co., Ltd. | Protein combination-based Fv library, and preparation method therefor |
WO2014176439A1 (fr) | 2013-04-25 | 2014-10-30 | Sutro Biopharma, Inc. | Utilisation de la protéine lambda gam dans la technologie d'affichage de ribosomes |
EP2989239B1 (fr) * | 2013-04-25 | 2018-07-04 | Sutro Biopharma, Inc. | Sélection de fragments fab au moyen d'une technologie de présentation sur ribosome |
RU2539752C2 (ru) * | 2013-05-23 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
EP3022221B1 (fr) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Anticorps humanisés comprenant des régions déterminant la complémentarité ultralongues |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
ES2837392T3 (es) | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
WO2015057906A1 (fr) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Agonistes 1 du récepteur cd200 |
GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US10435694B2 (en) * | 2014-03-14 | 2019-10-08 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
EP3119194B1 (fr) | 2014-03-21 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Animaux non humains qui produisent des protéines de liaison monodomaine |
IL292311A (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
MX2016012873A (es) | 2014-04-04 | 2017-03-07 | Bionomics Inc | Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5). |
GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
CA2954780A1 (fr) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralisation d'anticorps anti-grippe b et leurs utilisations |
AU2015308625A1 (en) | 2014-08-29 | 2017-04-20 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind OprF and Oprl |
JP6709215B2 (ja) | 2014-10-27 | 2020-06-10 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 抗tim−3抗体 |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
JP6831783B2 (ja) | 2014-11-14 | 2021-02-17 | ノバルティス アーゲー | 抗体薬物コンジュゲート |
EP3026060A1 (fr) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Anticorps humanisé, ou fragment de celui-ci spécifique pour CD45R0 |
SG11201704548PA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
EP3246434A1 (fr) * | 2015-01-13 | 2017-11-22 | Ewha University-Industry Collaboration Foundation | Procédé de préparation d'une nouvelle bibliothèque d'anticorps et bibliothèque ainsi préparée |
JP2018510865A (ja) * | 2015-03-10 | 2018-04-19 | ソレント・セラピューティクス・インコーポレイテッド | Psmaに結合する抗体医薬 |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
WO2016164656A1 (fr) * | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Anticorps thérapeutiques qui se lient à cd38 |
SG10201909308XA (en) | 2015-04-17 | 2019-11-28 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
MA42043A (fr) | 2015-05-07 | 2018-03-14 | Agenus Inc | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci |
EP3297663A4 (fr) | 2015-05-18 | 2018-12-19 | Agensys, Inc. | Anticorps qui se lient aux protéines axl |
JP6857138B2 (ja) | 2015-05-18 | 2021-04-14 | アジェンシス,インコーポレイテッド | Axlタンパク質に結合する抗体 |
MX2017015189A (es) | 2015-06-01 | 2018-04-13 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
WO2017008049A1 (fr) * | 2015-07-08 | 2017-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Anticorps hétérotypiques spécifiques contre le rotavirus humain |
ES2913530T3 (es) | 2015-08-12 | 2022-06-02 | Novartis Ag | Métodos para tratar trastornos oftálmicos |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
CA2999284C (fr) | 2015-09-30 | 2023-06-13 | Igm Biosciences A/S | Molecules de liaison a chaine j modifiee |
EP3184547A1 (fr) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anticorps anti-tpbg et procédés d'utilisation |
DK3374398T3 (da) | 2015-11-10 | 2020-06-08 | Medimmune Llc | Bindingsmolekyler, som er specifikke for asct2, og anvendelser deraf |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
WO2017096281A1 (fr) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anticorps anti-ox40 et leurs procédés d'utilisation |
CA3006963A1 (fr) * | 2015-12-03 | 2017-06-08 | Ludwig Institute For Cancer Research Ltd. | Anticorps anti-ox40 et leurs procedes d'utilisation |
CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
CN105693821A (zh) * | 2016-01-08 | 2016-06-22 | 中国药科大学 | 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽,其筛选方法,鉴定和用途 |
MX2018008302A (es) * | 2016-01-08 | 2018-09-21 | Aimm Therapeutics Bv | Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. |
WO2017123685A1 (fr) | 2016-01-13 | 2017-07-20 | Medimmune, Llc | Méthode de traitement de la grippe a |
US11505599B2 (en) | 2016-01-14 | 2022-11-22 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for Foxp3-derived peptides |
CN108697799A (zh) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | 抗lgr5单克隆抗体的施用 |
JP7046828B2 (ja) * | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
GEP20227382B (en) * | 2016-06-14 | 2022-05-25 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
EP3475446A1 (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées |
MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
WO2018049083A1 (fr) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Anticorps contre des épitopes spécifiques à l'oxydation |
CN118005799A (zh) * | 2016-09-23 | 2024-05-10 | 马伦戈治疗公司 | 包含λ轻链和κ轻链的多特异性抗体分子 |
WO2018075621A1 (fr) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Anticorps d'orthopoxvirus humain et leurs procédés d'utilisation |
WO2018081755A1 (fr) * | 2016-10-29 | 2018-05-03 | University Of Miami | Anticorps contre le virus zika |
WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
SG10201913470SA (en) | 2016-11-08 | 2020-03-30 | Regeneron Pharma | Antigen-binding proteins that antagonize leptin receptor |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
CN109922832A (zh) * | 2016-11-10 | 2019-06-21 | 免疫医疗有限责任公司 | 对asct2具有特异性的结合分子及其用途 |
CA3045466A1 (fr) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-pd-l1 radiomarques pour imagerie immuno-pet |
KR20190118172A (ko) | 2017-02-08 | 2019-10-17 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
EP3582782B1 (fr) | 2017-02-17 | 2023-06-07 | Fred Hutchinson Cancer Center | Traitements d'association pour le traitement de cancers associés à bcma et de troubles auto-immuns |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
WO2018162944A1 (fr) * | 2017-03-04 | 2018-09-13 | Shenzhen Runshin Bioscience | Anticorps recombinants dirigés contre la mort programmée 1 (pd-1) et leurs utilisations |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
US11976121B2 (en) | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
CN111448211B (zh) * | 2017-07-31 | 2024-06-07 | 翠舒拉治疗股份有限公司 | 抗cd39抗体、包含抗cd39抗体的组合物和使用抗cd39抗体的方法 |
KR20200084320A (ko) * | 2017-08-18 | 2020-07-10 | 그릿스톤 온콜로지, 인코포레이티드 | 공유 항원을 표적으로 하는 항원-결합 단백질 |
US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
MX2020004243A (es) | 2017-11-01 | 2020-09-25 | Juno Therapeutics Inc | Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b. |
US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
AU2018367622B2 (en) * | 2017-11-20 | 2022-12-22 | Nantbio, Inc. | mRNA display antibody library and methods |
SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
CN111655729B (zh) | 2017-12-19 | 2023-10-20 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
WO2019143884A1 (fr) * | 2018-01-19 | 2019-07-25 | Vanderbilt University | Clonotypes d'anticorps du vih conservés et méthodes d'utilisation |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
EP3755721A4 (fr) * | 2018-02-20 | 2021-12-22 | Dragonfly Therapeutics, Inc. | Protéines de liaison multi-spécifiques qui se lient à cd33, nkg2d et cd16, et procédés d'utilisation |
KR20200131862A (ko) | 2018-03-13 | 2020-11-24 | 터스크 테라퓨틱스 리미티드 | 종양 특이적 세포 고갈에 대한 항-cd25 |
WO2019195796A1 (fr) | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | Anticorps agoniste du récepteur de la leptine destiné à être utilisé dans le traitement d'un dysfonctionnement métabolique ou d'une hypoleptinémie |
EP3553082A1 (fr) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique du cerveau |
EP3553079A1 (fr) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique de type c |
EP3553081A1 (fr) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique auriculaire |
WO2020010235A1 (fr) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Cellules car-t qui ciblent des antigènes de cellules b |
US10954508B2 (en) | 2018-07-08 | 2021-03-23 | Specifica Inc. | Antibody libraries with maximized antibody developability characteristics |
AU2019329984A1 (en) | 2018-08-28 | 2021-03-11 | Fred Hutchinson Cancer Center | Methods and compositions for adoptive T cell therapy incorporating induced notch signaling |
CN109553680B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns4B8及其应用 |
CA3124941A1 (fr) * | 2019-01-31 | 2020-08-06 | Nantbio, Inc. | Bibliotheque d'anticorps d'affichage d'arnm et procedes |
WO2020205775A1 (fr) * | 2019-03-29 | 2020-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anticorps dirigés contre la protéine 1 de mort cellulaire programmée (pd1) et leurs utilisations |
WO2020219774A1 (fr) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Conjugués anticorps-médicaments d'antracycline et leurs utilisations |
WO2020247883A2 (fr) * | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Évolution profonde de biomolécules par mutation |
GB2600274A (en) | 2019-06-07 | 2022-04-27 | Scribe Therapeutics Inc | Engineered CasX systems |
AU2020290579A1 (en) * | 2019-06-14 | 2021-12-16 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 and methods of use thereof |
JP2022539212A (ja) * | 2019-07-02 | 2022-09-07 | スロゼン オペレーティング, インコーポレイテッド | 単一特異性抗Frizzled抗体および使用の方法 |
US20210102195A1 (en) * | 2019-09-23 | 2021-04-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
AU2020371725A1 (en) * | 2019-10-24 | 2022-05-26 | Cedars-Sinai Medical Center | Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof |
CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
CN116113420A (zh) * | 2020-04-27 | 2023-05-12 | 特韦斯特生物科学公司 | 用于冠状病毒的变异核酸文库 |
WO2021236998A2 (fr) * | 2020-05-20 | 2021-11-25 | The Trustees Of Columbia University In The City Of New York | Anticorps neutralisants puissants contre le sras-cov-2, leur génération et leurs utilisations |
CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
EP4165171A1 (fr) | 2020-06-12 | 2023-04-19 | Nkarta, Inc. | Cellules tueuses naturelles génétiquement modifiées pour immunothérapie anticancéreuse dirigée contre cd70 |
US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
IL303290A (en) * | 2020-12-04 | 2023-07-01 | Equillium Inc | Methods for selective targeting of CD6 HIGH cells and reduction of EFF T cell activity |
WO2022150787A2 (fr) * | 2021-01-11 | 2022-07-14 | Adimab, Llc | Domaines ch1 variants et domaines cl variants ingéniérisés pour un appariement de chaînes préférentiel et anticorps multispécifiques les comprenant |
WO2022192661A1 (fr) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Anticorps neutralisant le sras-cov-2 et leurs utilisations |
IL309422A (en) | 2021-06-17 | 2024-02-01 | Atreca Inc | Antibodies against CSP |
KR20240033025A (ko) * | 2021-07-12 | 2024-03-12 | 엔카르타, 인크. | Bcma-지시된 세포 면역요법 조성물 및 방법 |
CA3227150A1 (fr) * | 2021-07-23 | 2023-01-26 | The Trustees Of Columbia University In The City Of New York | Caracterisation d'anticorps monoclonaux puissants et largement neutralisants contre le sars-cov-2, ses variants et coronavirus associes et procedes d'utilisation |
WO2023026236A1 (fr) * | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Radioconjugués anti-psma et leurs utilisations |
CN118176213A (zh) | 2021-08-27 | 2024-06-11 | 詹森生物科技公司 | 抗psma抗体及其用途 |
AU2022340645A1 (en) * | 2021-09-02 | 2024-02-29 | Memorial Hospital For Cancer And Allied Diseases | Anti-cd33 antibodies and uses thereof |
AU2022340644A1 (en) * | 2021-09-02 | 2024-02-29 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting cd33 and uses thereof |
WO2023034950A2 (fr) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anticorps anti-hcmv et leurs fragments de liaison à l'antigène |
US20230265217A1 (en) * | 2021-10-27 | 2023-08-24 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
WO2023168432A2 (fr) * | 2022-03-04 | 2023-09-07 | Coagulant Therapeutics Corporation | Anticorps humains dirigés contre la protéine c activée et leurs utilisations |
WO2024077104A2 (fr) * | 2022-10-04 | 2024-04-11 | Mink Therapeutics, Inc. | Cellules car-t tueuse naturelle invariante (inkt) anti-protéine d'activation des fibroblastes (fap) et leurs utilisations |
CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
CN117986346A (zh) * | 2024-04-07 | 2024-05-07 | 中国人民解放军军事科学院军事医学研究院 | 一种tpo模拟肽及其应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
EP0494955B1 (fr) | 1989-10-05 | 1998-07-15 | Optein, Inc. | Synthese et isolation sans cellule de nouveaux genes et de nouveaux polypeptides |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
EP0972041B2 (fr) | 1997-04-04 | 2017-01-18 | Millennium Pharmaceuticals, Inc. | Nouvelles compositions contenant des proteines d'origine humaine delta3 |
US6664098B1 (en) | 1997-05-14 | 2003-12-16 | Asahi Kasei Kabushiki Kaisha | Differentiation inhibitory agent |
WO2000006726A2 (fr) | 1998-07-27 | 2000-02-10 | Amgen Inc. | Polypeptides relatifs a delta |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
MEP13708A (en) | 2000-06-23 | 2010-06-10 | Bayer Schering Pharma Ag | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
JP2005503792A (ja) | 2001-08-22 | 2005-02-10 | ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ | ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター |
WO2003035842A2 (fr) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Controle d'hybridation sur variation de sequence |
JP2005526518A (ja) * | 2002-05-20 | 2005-09-08 | アブマクシス,インコーポレイティド | タンパク質ライブラリーのinsilico作成と選択 |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2005023993A2 (fr) | 2003-09-09 | 2005-03-17 | Integrigen, Inc. | Procedes et compositions de generation de genes d'anticorps humains de lignee germinale |
CA2561264A1 (fr) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Variantes d'immunoglobuline a l'exterieur de la region fc |
US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
EP1848672A4 (fr) | 2005-02-01 | 2009-11-04 | Morphosys Ag | Banques et methodes permettant d'isoler des anticorps |
CA2627075A1 (fr) | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Ultra-humanisation d'anticorps par production et analyse de librairies cdr matures predites de type blast et cohorte |
JP5489465B2 (ja) | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Dll4アンタゴニストによって腫瘍増殖を阻害する治療方法 |
US20090318308A1 (en) | 2006-05-30 | 2009-12-24 | Millegen | Highly diversified antibody libraries |
AU2007256617A1 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
MX2008015541A (es) | 2006-06-06 | 2008-12-18 | Genentech Inc | Anticuerpos anti-dll4 y metodos que los usan. |
MY150092A (en) | 2006-08-07 | 2013-11-29 | Regeneron Pharma | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
WO2008042236A2 (fr) * | 2006-09-29 | 2008-04-10 | Oncomed Pharmaceuticals, Inc. | Compositions et procédés permettant de diagnostiquer et de traiter le cancer |
US20080100597A1 (en) | 2006-10-25 | 2008-05-01 | Macrovision Corporation | Method and apparatus to improve playability in overscan areas of a TV display |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
EP2125013A4 (fr) | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | Inhibiteurs de la signalisation dll4 et utilisations associees |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
-
2009
- 2009-11-04 DK DK09748671.6T patent/DK2356270T3/da active
- 2009-11-04 US US13/128,219 patent/US9221902B2/en active Active
- 2009-11-04 EP EP09748672A patent/EP2356146A1/fr not_active Withdrawn
- 2009-11-04 JP JP2011535651A patent/JP2012508017A/ja active Pending
- 2009-11-04 AU AU2009313560A patent/AU2009313560B2/en not_active Ceased
- 2009-11-04 CA CA2742969A patent/CA2742969A1/fr not_active Abandoned
- 2009-11-04 US US13/128,236 patent/US9403904B2/en active Active
- 2009-11-04 AU AU2009313551A patent/AU2009313551B2/en not_active Ceased
- 2009-11-04 EP EP09748671.6A patent/EP2356270B1/fr active Active
- 2009-11-04 WO PCT/US2009/063303 patent/WO2010054010A1/fr active Application Filing
- 2009-11-04 CA CA2742968A patent/CA2742968C/fr not_active Expired - Fee Related
- 2009-11-04 WO PCT/US2009/063299 patent/WO2010054007A1/fr active Application Filing
- 2009-11-04 JP JP2011535649A patent/JP5882058B2/ja active Active
-
2015
- 2015-08-10 JP JP2015157842A patent/JP2016040246A/ja active Pending
- 2015-12-04 US US14/959,940 patent/US10774138B2/en active Active
-
2016
- 2016-02-03 JP JP2016018531A patent/JP2016127850A/ja active Pending
- 2016-07-07 AU AU2016204719A patent/AU2016204719A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201622A patent/AU2018201622A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,749 patent/US20200399359A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110318339A1 (en) | 2011-12-29 |
AU2009313560B2 (en) | 2016-04-14 |
US10774138B2 (en) | 2020-09-15 |
AU2009313551B2 (en) | 2015-12-17 |
AU2016204719A1 (en) | 2016-07-28 |
JP2012508016A (ja) | 2012-04-05 |
JP5882058B2 (ja) | 2016-03-09 |
EP2356146A1 (fr) | 2011-08-17 |
AU2009313551A1 (en) | 2010-05-14 |
CA2742968C (fr) | 2020-06-09 |
WO2010054007A1 (fr) | 2010-05-14 |
AU2018201622A1 (en) | 2018-03-29 |
CA2742969A1 (fr) | 2010-05-14 |
US20200399359A1 (en) | 2020-12-24 |
US9403904B2 (en) | 2016-08-02 |
EP2356270B1 (fr) | 2016-08-24 |
DK2356270T3 (da) | 2016-12-12 |
WO2010054010A1 (fr) | 2010-05-14 |
US20120058906A1 (en) | 2012-03-08 |
JP2012508017A (ja) | 2012-04-05 |
EP2356270A1 (fr) | 2011-08-17 |
JP2016040246A (ja) | 2016-03-24 |
US20160194627A1 (en) | 2016-07-07 |
AU2009313560A1 (en) | 2010-05-14 |
US9221902B2 (en) | 2015-12-29 |
JP2016127850A (ja) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2742968C (fr) | Bibliotheques combinatoires d'anticorps et leurs utilisations | |
CA2780221A1 (fr) | Procedes pour l'optimisation d'anticorps basee sur la maturation d'affinite | |
US8404445B2 (en) | Antibody libraries | |
JP2010029198A (ja) | 蛋白質/(ポリ)ペプチドライブラリー | |
KR20140069074A (ko) | 이온 농도 의존성 결합 분자 라이브러리 | |
US9550986B2 (en) | High-throughput antibody humanization | |
WO2009132287A2 (fr) | Bibliothèques de matériels génétiques comprenant de nouvelles conceptions cdr1, cdr2 et cdr3 hc et de nouvelles conceptions cdr1, cdr2 et cdr3 lc | |
JP2020534796A (ja) | エピトープ翻訳後修飾状態に特異的な抗体の開発方法及び開発のための組成物 | |
AU2004324464A1 (en) | Methods of optimizing antibody variable region binding affinity | |
RU2812861C1 (ru) | Библиотека зависимых от концентрации ионов связывающих молекул |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20141103 |
|
MKLA | Lapsed |
Effective date: 20211104 |